MX2018009913A - Aglutinantes max como moduladores myc y sus usos. - Google Patents
Aglutinantes max como moduladores myc y sus usos.Info
- Publication number
- MX2018009913A MX2018009913A MX2018009913A MX2018009913A MX2018009913A MX 2018009913 A MX2018009913 A MX 2018009913A MX 2018009913 A MX2018009913 A MX 2018009913A MX 2018009913 A MX2018009913 A MX 2018009913A MX 2018009913 A MX2018009913 A MX 2018009913A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- myc
- binders
- max
- modulators
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101150094258 mxi1 gene Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295996P | 2016-02-16 | 2016-02-16 | |
| PCT/US2017/018162 WO2017143059A1 (en) | 2016-02-16 | 2017-02-16 | Max binders as myc modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009913A true MX2018009913A (es) | 2018-11-29 |
Family
ID=58191662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009913A MX2018009913A (es) | 2016-02-16 | 2017-02-16 | Aglutinantes max como moduladores myc y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10106555B2 (OSRAM) |
| EP (1) | EP3416950A1 (OSRAM) |
| JP (1) | JP2019505548A (OSRAM) |
| KR (1) | KR20180107261A (OSRAM) |
| CN (1) | CN109071456A (OSRAM) |
| AU (1) | AU2017221422A1 (OSRAM) |
| BR (1) | BR112018016133A2 (OSRAM) |
| CA (1) | CA3012846A1 (OSRAM) |
| MX (1) | MX2018009913A (OSRAM) |
| RU (1) | RU2018132559A (OSRAM) |
| WO (1) | WO2017143059A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10106555B2 (en) | 2016-02-16 | 2018-10-23 | Massachusetts Institute Of Technology | Max binders as MYC modulators and uses thereof |
| CA3106118A1 (en) * | 2018-07-09 | 2020-01-16 | The Scripps Research Institute | Improved compounds for myc inhibition |
| WO2021092500A1 (en) * | 2019-11-08 | 2021-05-14 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (iap) protein antagonists |
| CN111274691A (zh) * | 2020-01-16 | 2020-06-12 | 西安交通大学 | 一种分析预测max相材料可形成能力的方法 |
| EP4118081A1 (en) | 2020-03-27 | 2023-01-18 | Landos Biopharma, Inc. | Plxdc2 ligands |
| EP4277901A1 (en) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
| CN116908444B (zh) * | 2023-09-13 | 2023-12-19 | 中国医学科学院北京协和医院 | 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02191695A (ja) | 1989-01-20 | 1990-07-27 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02194085A (ja) | 1989-01-24 | 1990-07-31 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02196887A (ja) | 1989-01-26 | 1990-08-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02208392A (ja) | 1989-02-08 | 1990-08-17 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02222488A (ja) | 1989-02-23 | 1990-09-05 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227490A (ja) | 1989-02-28 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227489A (ja) | 1989-02-28 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227491A (ja) | 1989-03-01 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02242882A (ja) | 1989-03-16 | 1990-09-27 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02247280A (ja) | 1989-03-20 | 1990-10-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02247282A (ja) | 1989-03-22 | 1990-10-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02255794A (ja) | 1989-03-29 | 1990-10-16 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02255793A (ja) | 1989-03-30 | 1990-10-16 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| US5965574A (en) | 1996-08-13 | 1999-10-12 | Chen; Yuhpyng Liang | Heteroaryl amines as novel acetylcholinesterase inhibitors |
| JPH08231541A (ja) | 1995-03-01 | 1996-09-10 | Nippon Soda Co Ltd | イミダゾリン誘導体および除草剤 |
| WO2000018746A1 (en) | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders |
| WO2000023451A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| UA82827C2 (en) | 2000-12-18 | 2008-05-26 | Inhibitors against the production and release of inflammatory cytokines | |
| US6452014B1 (en) | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
| JP2003057783A (ja) | 2001-08-21 | 2003-02-26 | Konica Corp | 銀色調を改良した光熱写真画像形成材料 |
| JP2003075955A (ja) | 2001-09-03 | 2003-03-12 | Konica Corp | 銀色調を改良した光熱写真画像形成材料 |
| JP2003075957A (ja) | 2001-09-07 | 2003-03-12 | Konica Corp | スケイル模様のない光熱写真画像形成材料 |
| CA2460541A1 (en) | 2001-09-14 | 2003-04-03 | Helle Birk Olsen | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer |
| US20050042674A9 (en) | 2002-02-21 | 2005-02-24 | Lin Yu | Common ligand mimics: thiazolidinediones and rhodanines |
| GB2387172A (en) | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
| US7348348B2 (en) | 2002-04-30 | 2008-03-25 | Merck & Co. Inc. | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
| JP4211433B2 (ja) | 2002-08-14 | 2009-01-21 | 三菱化学株式会社 | 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子 |
| WO2004080989A1 (ja) | 2003-03-10 | 2004-09-23 | Sumitomo Chemical Company Limited | フラン化合物の製造方法 |
| US7777051B2 (en) | 2003-05-13 | 2010-08-17 | Icagen, Inc. | Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| EP1677794B1 (en) | 2003-09-12 | 2014-12-03 | Elixir Pharmaceuticals, Inc. | Methods of treating disorder |
| US20060074124A1 (en) | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
| WO2005033090A1 (ja) | 2003-10-06 | 2005-04-14 | Sumitomo Chemical Company, Limited | 芳香族化合物 |
| WO2006005683A1 (en) | 2004-07-09 | 2006-01-19 | Novo Nordisk A/S | Phamaceutical preparations comprising insulin |
| JP2006084592A (ja) | 2004-09-14 | 2006-03-30 | Fuji Photo Film Co Ltd | 感光性組成物 |
| RS51351B (sr) | 2005-07-20 | 2011-02-28 | Aventis Pharma S.A. | 1,4-dihidropiridin-kondenzovani hterocikli, postupci za njihovo dobijanje, upotreba i kompozicije koje ih sadrže |
| WO2007047604A2 (en) | 2005-10-18 | 2007-04-26 | Elixir Pharmaceuticals, Inc. | Sirt1 inhibition |
| JP4931434B2 (ja) | 2006-02-14 | 2012-05-16 | 株式会社ダイセル | アミノ基含有アダマンタン誘導体とその製造方法 |
| WO2007146712A2 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| WO2008012010A1 (en) | 2006-07-27 | 2008-01-31 | Ucb Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| JP2011510044A (ja) | 2008-01-24 | 2011-03-31 | ユセベ ファルマ ソシエテ アノニム | シクロブトキシ基を含む化合物 |
| WO2009108905A2 (en) | 2008-02-28 | 2009-09-03 | Life Technologies Corporation | Fluorescence polarization herg assay |
| KR101712576B1 (ko) | 2008-11-10 | 2017-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| EP2365969B1 (en) | 2008-11-20 | 2017-03-22 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Novel anti-biofilm agents |
| US20120040916A1 (en) * | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| JP5046213B2 (ja) | 2009-03-12 | 2012-10-10 | 独立行政法人科学技術振興機構 | 光学活性アルコール化合物の製法 |
| WO2011063502A1 (en) | 2009-11-24 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| AU2010326268B2 (en) | 2009-12-04 | 2016-11-03 | Senhwa Biosciences, Inc. | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors |
| JP5641663B2 (ja) | 2010-09-10 | 2014-12-17 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体 |
| EP2711363A1 (en) | 2011-05-11 | 2014-03-26 | Idemitsu Kosan Co., Ltd | Novel compound, material for organic electroluminescence device, and organic electroluminescence device |
| KR20140060484A (ko) | 2011-09-13 | 2014-05-20 | 이데미쓰 고산 가부시키가이샤 | 축합 복소 방향족 유도체, 유기 전계 발광 소자용 재료 및 그것을 이용한 유기 전계 발광 소자 |
| WO2013177241A1 (en) | 2012-05-22 | 2013-11-28 | Trustees Of Dartmouth College | Method for synthesizing cycloalkanyl(b}indoles, cycloalkanyl(b) benzofurans, cycloalkanyl(b)benzothiophenes, compounds and methods of use |
| SMT202000713T1 (it) * | 2012-12-07 | 2021-03-15 | Vertex Pharma | Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro |
| WO2014132971A1 (ja) | 2013-02-28 | 2014-09-04 | 住友化学株式会社 | 縮合複素環化合物及びその有害生物防除用途 |
| US8901164B2 (en) * | 2013-03-07 | 2014-12-02 | University Of Maryland, Baltimore | Amphipathic and other double-sided alpha-helix mimetics based on a 1,2-diphenylacetylene scaffold |
| BR112015022417A2 (pt) | 2013-03-14 | 2017-07-18 | Convergene Llc | métodos e composições para inibição de proteínas contendo bromodomínio |
| US9242944B2 (en) | 2013-03-27 | 2016-01-26 | University Of Maryland, Baltimore | Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability |
| US11066398B2 (en) | 2013-12-11 | 2021-07-20 | The Scripps Research Institute | Small molecule c-Myc inhibitors |
| AU2015360416A1 (en) | 2014-12-10 | 2017-06-08 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| US10106555B2 (en) | 2016-02-16 | 2018-10-23 | Massachusetts Institute Of Technology | Max binders as MYC modulators and uses thereof |
-
2017
- 2017-02-16 US US15/435,003 patent/US10106555B2/en active Active
- 2017-02-16 EP EP17708095.9A patent/EP3416950A1/en not_active Withdrawn
- 2017-02-16 KR KR1020187026354A patent/KR20180107261A/ko not_active Withdrawn
- 2017-02-16 JP JP2018543356A patent/JP2019505548A/ja active Pending
- 2017-02-16 AU AU2017221422A patent/AU2017221422A1/en not_active Abandoned
- 2017-02-16 WO PCT/US2017/018162 patent/WO2017143059A1/en not_active Ceased
- 2017-02-16 MX MX2018009913A patent/MX2018009913A/es unknown
- 2017-02-16 CA CA3012846A patent/CA3012846A1/en not_active Abandoned
- 2017-02-16 BR BR112018016133A patent/BR112018016133A2/pt not_active Application Discontinuation
- 2017-02-16 CN CN201780011783.5A patent/CN109071456A/zh active Pending
- 2017-02-16 RU RU2018132559A patent/RU2018132559A/ru not_active Application Discontinuation
-
2018
- 2018-10-22 US US16/167,238 patent/US10865213B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017143059A1 (en) | 2017-08-24 |
| US20170233405A1 (en) | 2017-08-17 |
| EP3416950A1 (en) | 2018-12-26 |
| US10865213B2 (en) | 2020-12-15 |
| US20190144466A1 (en) | 2019-05-16 |
| BR112018016133A2 (pt) | 2019-01-02 |
| AU2017221422A1 (en) | 2018-08-16 |
| US10106555B2 (en) | 2018-10-23 |
| JP2019505548A (ja) | 2019-02-28 |
| CN109071456A (zh) | 2018-12-21 |
| CA3012846A1 (en) | 2017-08-24 |
| KR20180107261A (ko) | 2018-10-01 |
| RU2018132559A (ru) | 2020-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009913A (es) | Aglutinantes max como moduladores myc y sus usos. | |
| AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| MX2018009633A (es) | Inhibidor de indoleamina-2,3-dioxigenasa (ido). | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| MX2018009496A (es) | Degradadores selectivos del receptor de estrogeno y sus usos. | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| JOP20190151A1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| NZ754051A (en) | Novel antibodies and uses thereof | |
| EP4566675A3 (en) | Heterocyclic compounds as immunomodulators | |
| WO2018226622A8 (en) | Compounds for treating huntington's disease | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| WO2017176957A8 (en) | Mdm2 protein degraders | |
| MA40074A (fr) | Composés liant ras multivalents | |
| EP4353235A3 (en) | Nlrp3 modulators | |
| EP4285906A3 (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
| MX2020012679A (es) | Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos. | |
| EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| WO2015108998A3 (en) | Cartilage targeting agents and their use | |
| MY192861A (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| HK1254954A1 (zh) | Lpt-723和免疫检查点抑制剂组合物及其治疗方法 | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. |